Study of NTQ2494 tablets for advanced blood cancer
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests an oral medication (NTQ2494) for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. It aims to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have acute myeloid leukemia (AML) that has returned or not improved after treatment.
- You are able to do daily activities with little or no help (ECOG score 0-2).
- Your major organs (like heart, liver, kidneys) and bone marrow are working well.
- You have not had chemotherapy, targeted therapy, or other cancer treatments in the last 2 weeks (or 5 half-lives, whichever is longer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment, CT1390B, for people whose acute myeloid leukemia (AML) has come back or not responded to other treatments. The goal is to see if it is safe and effective.
This trial tests a new treatment called CT0991 for people with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. It focuses on patients whose cancer cells show a high level of a protein called CD38.
This trial tests a new daily tablet (TQB3911) for people with chronic myeloid leukemia (CML) whose current targeted therapy (TKI) has stopped working or caused side effects. The goal is to see if this new drug is safe and can better control the leukemia.
This trial tests an experimental oral capsule called TQB3019 for people with advanced blood cancers that have come back or not improved with other treatments. The goal is to see if the drug is safe and to find the right dose.
This trial tests a new tablet, TQB3455, for people with certain blood cancers (MDS or AML) that have an IDH2 mutation. The goal is to see if the drug can help when other treatments haven't worked or aren't possible.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
Hear when a new Relapsed/Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.